About Precision BioSciences, Inc.
https://www.precisionbiosciences.comPrecision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders.
CEO
Michael Amoroso
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2024-02-14 | Reverse | 1:30 |
ETFs Holding This Stock
Summary
Showing Top 3 of 14
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
OUP MANAGEMENT CO., LLC
Shares:1.12M
Value:$4.64M
COWEN INC.
Shares:1.08M
Value:$4.48M
BLEICHROEDER LP
Shares:1.07M
Value:$4.44M
Summary
Showing Top 3 of 78
About Precision BioSciences, Inc.
https://www.precisionbiosciences.comPrecision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $13K ▼ | $20.01M ▼ | $-21.77M ▲ | -167.48K% ▼ | $-1.84 ▲ | $-20.74M ▲ |
| Q2-2025 | $18K ▼ | $21.2M ▼ | $-23.52M ▼ | -130.67K% ▼ | $-2.13 ▲ | $-22.47M ▼ |
| Q1-2025 | $29K ▼ | $22.14M ▼ | $-20.57M ▼ | -70.91K% ▼ | $-2.3 ▲ | $-19.51M ▼ |
| Q4-2024 | $638K ▲ | $25.48M ▲ | $-17.75M ▼ | -2.78K% ▲ | $-2.51 ▼ | $-16.6M ▼ |
| Q3-2024 | $576K | $21.85M | $-16.43M | -2.85K% | $-2.25 | $-15.16M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $44.87M ▼ | $93.51M ▼ | $76.88M ▲ | $16.63M ▼ |
| Q2-2025 | $62.24M ▼ | $108.93M ▼ | $74.87M ▼ | $34.05M ▼ |
| Q1-2025 | $77.22M ▼ | $124.41M ▼ | $75.07M ▼ | $49.34M ▼ |
| Q4-2024 | $86.31M ▼ | $136.39M ▼ | $80M ▼ | $56.39M ▼ |
| Q3-2024 | $101.2M | $153.26M | $88.39M | $64.87M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-21.77M ▲ | $-15.27M ▲ | $17K ▲ | $1.66M ▼ | $-17.37M ▼ | $-15.27M ▲ |
| Q2-2025 | $-23.52M ▼ | $-20.27M ▼ | $-12K ▲ | $5.3M ▼ | $-14.98M ▼ | $-20.27M ▼ |
| Q1-2025 | $-20.57M ▼ | $-19.05M ▼ | $-314K ▼ | $10.69M ▲ | $-8.68M ▲ | $-19.37M ▼ |
| Q4-2024 | $-17.75M ▼ | $-18.68M ▼ | $-97K ▼ | $5.92M ▲ | $-12.86M ▼ | $-18.78M ▼ |
| Q3-2024 | $-16.43M | $-5.91M | $-64K | $3.73M | $-2.24M | $-5.98M |
Revenue by Products
| Product | Q4-2021 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Collaboration and License | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Operating Segments | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Food Segment | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Therapeutics Segment | $10.00M ▲ | $0 ▼ | $0 ▲ | $0 ▲ |
CEO
Michael Amoroso
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2024-02-14 | Reverse | 1:30 |
ETFs Holding This Stock
Summary
Showing Top 3 of 14
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
OUP MANAGEMENT CO., LLC
Shares:1.12M
Value:$4.64M
COWEN INC.
Shares:1.08M
Value:$4.48M
BLEICHROEDER LP
Shares:1.07M
Value:$4.44M
Summary
Showing Top 3 of 78